NEW YORK--(BUSINESS WIRE)--
Rowley Law PLLC is investigating potential claims against Kite Pharma, Inc. (NASDAQ: KITE) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Gilead Sciences, Inc. for $180.00 per share in cash. The transaction is valued at approximately $11.9 billion and is expected to close in the fourth quarter of 2017.
If you are a Kite Pharma, Inc. shareholder and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/kitepharma. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at [email protected], or by telephone at 914-400-1920 or 844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005683/en/